On July 9, Definium Therapeutics rose 5.09% in regular trading, trading at $47.34 per share with turnover of $67.50 million.

The rally continues to be driven by the companys core product DT120 orally disintegrating tablet achieving positive topline results in its pivotal Phase 3 EMERGE study for major depressive disorder. The study met its primary endpoint and all key secondary efficacy endpoints, demonstrating statistically significant improvement over placebo with a favorable safety profile. Following the data readout, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.

Additionally, the company closed an upsized public offering of approximately 23.7 million shares at $34 each, raising gross proceeds of $805 million, including the full exercise of underwriter overallotment options. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. The combination of validated clinical data and strengthened financial position continues to support upward momentum in the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)